Last reviewed · How we verify

NCT07139756: HYPOPARK

Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension

Not yet recruiting Last updated 24 August 2025
What this trial tests

trial testing Lower body negative pressure in Parkinson Disease in 130 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
30 September 2027
31 March 2028

Quick facts

Lead sponsorCentre Hospitalier Universitaire Vaudois
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment130
Start date1 October 2025
Primary completion30 September 2027
Estimated completion31 March 2028
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire Vaudois

Who can join

Adults 18 to 75, any sex, with Parkinson Disease or Orthostatic Hypotension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1 objective: test the feasibility of using a 3Tesla MRI scanner instead of a 7Tesla MRI scanner to measure brainstem responses to LBNP in healthy participants. Phase 2 primary objective: compare the brainstem responses to LBNP in patients with PD associated with OH to PD patients without OH using BOLD fMRI

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lower body negative pressure

Trials testing the same drug.

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire Vaudois trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07139756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing